Determinants of response to repeat hepatitis B vaccination in HIV-infected prior non-responders

Rowley, Kate; Payne, Brendan; Schmid, Matthias

doi:10.1016/j.jinf.2014.02.014

Cited by 9 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the standard-dose group in our study had a 51% response to HBV revaccination. Looking at previously published data from studies using a standard-dose regimen, this response rate is higher than the 27% reported in Rowney et al and the 29% reported by Bloom et al, but lower than the 59% response reported by Psevdos et al and the 67% reported by Rey et al The wide difference in the HBV vaccination response rate among studies using standard dosage could be related to several factors: study design, patient selection, intervals between vaccination doses, and type of vaccine used . Difference in patient selection, number or prior vaccine doses, and the use of a booster dose prior to randomization could explain the higher response in the ARNS B-BOOST trial as compared with the lower response with standard dosage found in our study.…”

Section: Discussionmentioning

confidence: 67%

“…Psevdos et al reported a response rate between 59% and 85% using a high-dose regimen at 0, 1, and 6 months in 101 retrospectively analyzed patients. Similarly, Rowley et al reported a 64% to 75% response to high-dose repeat HBV vaccinations. In their randomized clinical trial (the ANRS B-BOOST trial), Rey et al described a 74% response in a double-dose group using 0, 1, and 6 months interval dosage.…”

Section: Discussionmentioning

confidence: 92%

See 1 more Smart Citation

Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV

et al. 2021

View full text Add to dashboard Cite

Key Points Question What is the efficacy of a high-dose vaccine schedule compared with standard dosage for hepatitis B virus (HBV) revaccination in patients living with HIV? Findings In this randomized clinical trial including 107 adults at a single HIV and hepatology clinic in Chile, 72% of patients receiving a high dose of HBV vaccine achieved serological response as compared with 51% in the standard-dose group. Higher and longer-lasting hepatitis B surface antibody titers were seen in the high-dose group as well. Meaning These results suggest that a high-dose regimen may be superior to a standard-dose schedule for HBV revaccination to achieve seroprotection in patients living with HIV.

show abstract

Section: Discussionmentioning

confidence: 67%

Section: Discussionmentioning

confidence: 92%

Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These results were confirmed in sub-group analyses (< 350 and 350-500 CD4 cells/mm3). 57 Two retrospective studies found similar response rates of 67% 59 and 64% 28 to doubledose rescue vaccinations. Another retrospective study 60 found a response rate of 81.5% in subjects receiving an accelerated rescue schedule (40 mg at M0-1-2) after failure of a classic chedule.…”

Section: Strategies In Patients Who Were Vaccinated But Without Seropmentioning

confidence: 95%

Hepatitis B virus vaccination in HIV-infected people: A review

Catherine

Piroth

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

HBV immunization is highly recommended in people infected with HIV. However, the classical schedule used in the general population has been shown to be insufficient in people living with HIV. This review summarizes the main studies dealing with HBV vaccination in people living with HIV, depending on their baseline status (in particular, never vaccinated, already vaccinated, or with an isolated anti-HBc serological profile). It shows that reinforced 40µg intramuscular HBV vaccination schedules are now frequently recommended, either initially in people never vaccinated, or in the lack of an anamnestic response in other situations. Adjuvants cannot be currently recommended. Anti-HBs titers have to be checked 1 to 2 months following the last vaccine dose, and annually thereafter a booster is necessary if antiHBs titers decrease below 10 mIU/mL. In patients with a CD4 cell count <200/µL, guidelines recommend starting the vaccination regimen as soon as possible after HAART has been started.

show abstract

“…While there were no data on other HepB vaccine regimens in liver-transplanted children, several HepB vaccine regimens have been assessed in HIV-infected people. Several studies found a high response rate and a greater GMT of anti-HBs after 72 weeks of follow-up in multiple doses of the double-dose regimen [19][20][21][22][23][24]. Regarding these results, the international guidelines recommend a three double-dose rescue HepB vaccination in HIV-infected populations with anti-HB loss [18,25,26].…”

Section: Discussionmentioning

confidence: 99%

Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial

et al. 2022

View full text Add to dashboard Cite

A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised.

show abstract

Determinants of response to repeat hepatitis B vaccination in HIV-infected prior non-responders

Cited by 9 publications

References 5 publications

Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV

Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients With HIV

Hepatitis B virus vaccination in HIV-infected people: A review

Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial

Contact Info

Product

Resources

About